Koga-Yamakawa E - Search Results

1

Arabino-mycolates derived from cell-wall skeleton of Mycobacterium bovis BCG as a prominent structure for recognition by host immunity.

Miyauchi M, Murata M, Shibuya K, Koga-Yamakawa E, Uenishi Y, Kusunose N, Sunagawa M, Yano I, Kashiwazaki Y. Miyauchi M, et al. Among authors: koga yamakawa e. Drug Discov Ther. 2011 Jun;5(3):130-5. doi: 10.5582/ddt.2011.v5.3.130. Drug Discov Ther. 2011. PMID: 22466242 Free article.

2

Phagocytosis plays a dual role in activating dendritic cells; digestive production of active Toll-like receptor ligands and cooperation with Toll-like receptor signaling.

Miyauchi M, Murata M, Shibuya K, Koga-Yamakawa E, Yanagawa Y, Azuma I, Kashiwazaki Y. Miyauchi M, et al. Among authors: koga yamakawa e. Drug Discov Ther. 2010 Apr;4(2):135-43. Drug Discov Ther. 2010. PMID: 22491171 Free article.

3

Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer.

Koga-Yamakawa E, Dovedi SJ, Murata M, Matsui H, Leishman AJ, Bell J, Ferguson D, Heaton SP, Oki T, Tomizawa H, Bahl A, Takaku H, Wilkinson RW, Harada H. Koga-Yamakawa E, et al. Int J Cancer. 2013 Feb 1;132(3):580-90. doi: 10.1002/ijc.27691. Epub 2012 Jul 11. Int J Cancer. 2013. PMID: 22733292

4

TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice.

Koga-Yamakawa E, Murata M, Dovedi SJ, Wilkinson RW, Ota Y, Umehara H, Sugaru E, Hirose Y, Harada H, Jewsbury PJ, Yamamoto S, Robinson DT, Li CJ. Koga-Yamakawa E, et al. Cancer Immunol Immunother. 2015 Oct;64(10):1229-39. doi: 10.1007/s00262-015-1730-4. Epub 2015 Jun 20. Cancer Immunol Immunother. 2015. PMID: 26091797 Free PMC article.

5

Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy.

Dovedi SJ, Adlard AL, Ota Y, Murata M, Sugaru E, Koga-Yamakawa E, Eguchi K, Hirose Y, Yamamoto S, Umehara H, Honeychurch J, Cheadle EJ, Hughes G, Jewsbury PJ, Wilkinson RW, Stratford IJ, Illidge TM. Dovedi SJ, et al. Among authors: koga yamakawa e. Oncotarget. 2016 Mar 29;7(13):17035-46. doi: 10.18632/oncotarget.7928. Oncotarget. 2016. PMID: 26959743 Free PMC article.

6

DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects.

Ota Y, Nagai Y, Hirose Y, Hori S, Koga-Yamakawa E, Eguchi K, Sumida K, Murata M, Umehara H, Yamamoto S. Ota Y, et al. Among authors: koga yamakawa e. Front Immunol. 2023 Jan 30;14:1055671. doi: 10.3389/fimmu.2023.1055671. eCollection 2023. Front Immunol. 2023. PMID: 36793737 Free PMC article.

7

A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.

Adlard AL, Dovedi SJ, Telfer BA, Koga-Yamakawa E, Pollard C, Honeychurch J, Illidge TM, Murata M, Robinson DT, Jewsbury PJ, Wilkinson RW, Stratford IJ. Adlard AL, et al. Among authors: koga yamakawa e. Int J Cancer. 2014 Aug 15;135(4):820-9. doi: 10.1002/ijc.28711. Epub 2014 Jan 17. Int J Cancer. 2014. PMID: 24390981 Free PMC article.

8

Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies.

Spira A, Hansen AR, Harb WA, Curtis KK, Koga-Yamakawa E, Origuchi M, Li Z, Ertik B, Shaib WL. Spira A, et al. Among authors: koga yamakawa e. Target Oncol. 2021 Jul;16(4):461-469. doi: 10.1007/s11523-021-00813-6. Epub 2021 May 3. Target Oncol. 2021. PMID: 33939067 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters